Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GB Sciences Inc GBLX

Healthcare
GB Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company. It creates patented, disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. (GBSGB). The primary focus for the development of its lead program has been in evaluating suitable... see more

Recent & Breaking News (GREY:GBLX)

Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

GlobeNewswire January 11, 2022

Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

GlobeNewswire December 6, 2021

Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships

GlobeNewswire November 29, 2021

Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety

GlobeNewswire November 1, 2021

Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation

GlobeNewswire September 14, 2021

Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference

GlobeNewswire September 9, 2021

GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform

Accesswire July 27, 2021

GB Sciences Using AI Technology in Plant-Based Drug Discovery Research

Accesswire June 29, 2021

GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President

Accesswire June 17, 2021

GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals

Accesswire April 20, 2021

GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform

Accesswire April 7, 2021

GB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain Relief

Accesswire March 23, 2021

GB Sciences Begins Proof of Concept Studies with Michigan State University for the Treatment of Cytokine Release Syndrome

Accesswire January 25, 2021

GB Sciences Receives $4,150,000 and Completes the Sale of Its Louisiana Operations to Wellcana Plus

Accesswire January 12, 2021

GB Sciences Announces Issuance of US Patent for its Proprietary, Cannabinoid-Based Anti-Inflammatory Formulations

Accesswire December 8, 2020

GB Sciences Files Provisional Patent Application for the Treatment of Chronic Inflammation Utilizing Its Novel Cannabinoid Containing Complex Mixtures (CCCM)

Accesswire October 6, 2020

GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannabinoid Containing Complex Mixtures (CCCM(TM))

Accesswire August 26, 2020

GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment Market

Accesswire July 20, 2020

GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease

Accesswire May 4, 2020

GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada

Accesswire April 6, 2020